Testing Drug Eluting Paclitaxel Balloon Valvuloplasty in an Experimental Model of Aortic Stenosis
Balloon aortic valvuloplasty (BAV) was introduced in 1986 as an alternative non- surgical therapeutic option in elderly and high-risk patients with aortic stenosis . It generates small to moderate increase in the effective aortic valve area (AVA) and decline in the transvalvular pressure gradient (by average 50 %) which results in early symptomatic improvements in the majority of patients [2–5]. Nonetheless, clinical data demonstrates restenosis rates of the aortic valve occurring up to 83 % observed at 6 months and is almost universal within 1 year after the procedure [3, 6, 7]. Restenosis promptly revokes the improvement in symptoms and quality of life, which is so much valued especially in the elderly population with multiple comorbidities and limited life expectancy. The initial enthusiasm about BAV led to its more liberal use in high-risk patients but registry data indicated that it does not alter the natural history of aortic stenosis .
- 5.NHLBI Balloon Valvuloplasty Registry Participants. Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results from the NHLBI balloon valvuloplasty registry. Circulation. 1991;84:2383–97.Google Scholar
- 7.Tuzcu EM. Clinical outcomes from “Standard Therapy” in the P AR TNER inoperable patients. In: Paper presented at: Transcatheter cardiovascular therapeutics 2010, Washington, DC, 24 Sept 2010.Google Scholar
- 14.Leon M. Lessons learned from the PARTNER experience in the United States. In: Paper presented at: Transcatheter valve therapies 2010, Seattle, 6–9 June 2010.Google Scholar
- 30.Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol. 2010;298:H5–15.Google Scholar